We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Modified Glucose Meters Measure More Than Sugar

By LabMedica International staff writers
Posted on 11 Aug 2011
Point-of-care glucose meters have been adapted for other target molecules by coupling them with a class of molecular sensors called functional DNA sensors. More...


Functional DNA sensors use short segments of DNA that bind to specific targets and a number of functional DNAs and ribonucleic acids (RNAs) are available to recognize a wide variety of targets.

Chemists at the University of Illinois (Urbana-Champaign, IL, USA) modified the meters so that they can be used as simple, portable, inexpensive meters for a number of target molecules in blood, serum, water or food. The DNA segments, immobilized on magnetic particles, are bound to the enzyme invertase, which can catalyze conversion of sucrose to glucose. The user adds a sample of blood, serum, or water to the functional DNA sensor to test for drugs, disease markers, contaminants or other molecules. When the target molecule binds to the DNA, invertase is released into the solution. After removing the magnetic particle by a magnet, the glucose level of the sample rises in proportion to the amount of invertase released, so the user then can employ a glucose meter to quantify the target molecule in the original sample.

The scientists demonstrated using functional DNA with glucose meters to detect cocaine, the disease marker interferon, adenosine, and uranium. The two-step method could be used to detect any kind of molecule that a functional DNA or RNA can bind.

The scientists next plan to further simplify their method, which now requires users to first apply the sample to the functional DNA sensor and then to the glucose meter. Yu Li, PhD, the senior author of the study, said, "We are working on integrating the procedures into one step to make it even simpler. Our technology is new and, given time, it will be developed into an even more user-friendly format.” The study was published on July 24, 2011, in the journal Nature Chemistry.

Related Links:
University of Illinois




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.